Phase 1 N=40 Feasibility of Aromatherapy in an Awake Craniotomy Environment
Intracranial Pathology
Primary: Number of Consented Patients — 40 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=73 A Clinical Pharmacology Trial of Brexpiprazole Once-weekly (QW) Formulation Administered as Single and Multiple Oral Doses
Schizophrenia
Primary: Maximum Plasma Concentration (Cmax) of OPC-34712 Following Single Oral Administration of 24 mg and 48 mg QW Formulation or 2 mg Conventional Tablet in Cohrt1 — 25.37…
Phase 3 N=65 Photodynamic Therapy (PDT) With Metvix Cream 160 mg/g Versus PDT With Placebo Cream in Participants With Primary Nodular Basal Cell Carcinoma
Basal Cell Carcinoma
Primary: Number of Participants With Histologically Confirmed Complete Response — 25; 11 Participants
Phase 2 N=12 Effect of Perampanel on Peritumoral Hyperexcitability in HGG
Glioma, Malignant · Surgery · Seizures
Primary: Peritumoral HFO Rate — 2.5; 1.4 HFOs per minute
N/A N=74 Smoking Reduction In Gravid Substance Use Disorders
Tobacco Smoking in Mother Complicating Pregnancy · Tobacco Use Disorder · Tobacco Smoking
Primary: Prevalence of Smoking ≥ 10 Cigarettes/Day in Each Group at Final Measurement by Exhaled Carbon Monoxide Level — 22; 16 participants — p=0.06
Phase 1 N=14 Safety, Tolerability, and Pharmacokinetic (PK) Study of DHES0815A in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Breast Cancer
Breast Cancer
Primary: Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) With Severity Determined as Per National Cancer Institute Common Terminology Criteria for Adverse…
N/A N=376 A Study to go Back Into Records and Observe How People With Metastatic Renal Cell Carcinoma (mRCC) Who Received a Medicine Called Sunitinib Responded to This Medicine.
Carcinoma, Renal Cell · Clear-cell Metastatic Renal Cell Carcinoma
Primary: Objective Response Rate (ORR) According to Disease Risk Group in IMDC — 57.5; 44.6; 24.0 Percentage of participants
N/A N=10 CP1150 Sound Processor Speech Perception Compared With the Next Generation of Signal Processing Technology
Hearing Impairment, Sensorineural
Primary: Speech Perception in Quiet Using an CP1150 Sound Processor — 13.82; 11.53 percentage of correct words
N/A N=143 LSI (Lesion Index) Workflow Observational Study
Paroxysmal Atrial Fibrillation
Primary: Mean Achieved Lesion Index (LSI) Values — 4.9; 4.8; 4.9; 4.7 Lesion Index
Phase 1 N=38 A Study to Investigate the Effect of Impaired Hepatic Function on the Pharmacokinetics of Entrectinib in Volunteers With Different Levels of Hepatic Function
Hepatic Insufficiency
Primary: Maximum Observed Plasma Concentration (Cmax) of Entrectinib — 296.140; 213.570; 183.680; 235.990 nmol/L
Phase 1 N=80 Study of Open Label Losartan in COVID-19
COVID-19
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by Protocol Definition of AE — 24; 44 Participants
N/A N=75 An Exploratory stuDy of effectIveneSs and Safety of rivarOxaban in Patients With Left VEntricular Thrombus (R-DISSOLVE)
Ventricular Mural Thrombosis
Primary: Number of Participants With Left Ventricular Thrombus Resolution at 12 Weeks/Number of Participants at 12 Weeks — 50 Participants
Phase 1 N=5 IFx-Hu2.0 for the Treatment of Patients With Skin Cancer
Cutaneous Squamous Cell Carcinoma · Basal Cell Carcinoma
Primary: Rate of Adverse Events — 0; 0; 5 Participants
Phase 1 N=97 Safety, Tolerability and Pharmacokinetics of AM1476 in Healthy Subjects
Safety · Tolerability
Primary: Number of Participants With Treatment-Emergent Adverse Events — 3; 0; 0; 4 Participants
Phase 4 N=42 Trial Comparing Ceftriaxone Plus Azithromycin Versus Ceftriaxone for the Treatment of Gonorrhea
Neisseria Gonorrhoeae
Primary: Macrolide Resistance Determinants — 110.3; 167.53 normalized determinants/million reads — p=0.1026